Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001057248 | SCV001221731 | likely benign | not provided | 2023-02-01 | criteria provided, single submitter | clinical testing | |
Laboratory for Molecular Medicine, |
RCV001449744 | SCV001653019 | uncertain significance | not specified | 2020-08-13 | criteria provided, single submitter | clinical testing | The p.Ser2155Ser variant in CDH23 has not been previously reported in individuals with hearing loss or Usher syndrome, but has been identified in 0.0008% (1/112900) of European chromosomes by gnomAD. This variant is a silent variant and is not located within the splice consensus sequence, but computational prediction tools suggest a possible creation of a 3' splice site. However, this information is not predictive enough to determine pathogenicity. In summary, the clinical significance of the p.Ser2155Ser variant is uncertain. ACMG/AMP Criteria applied: PM2, PP3. |
Natera, |
RCV001832516 | SCV002095042 | uncertain significance | Usher syndrome type 1 | 2020-02-26 | no assertion criteria provided | clinical testing |